PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.68%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-2.25%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-16.28%
Negative EBIT growth while ADI is at 79.55%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-15.24%
Negative operating income growth while ADI is at 79.55%. Joel Greenblatt would press for urgent turnaround measures.
-14.95%
Negative net income growth while ADI stands at 70.82%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-12.50%
Negative EPS growth while ADI is at 70.97%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-13.75%
Negative diluted EPS growth while ADI is at 67.74%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.46%
Share reduction while ADI is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.88%
Reduced diluted shares while ADI is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.31%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-61.75%
Negative OCF growth while ADI is at 10.98%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-66.59%
Negative FCF growth while ADI is at 29.18%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
42.07%
Similar 10Y revenue/share CAGR to ADI's 45.72%. Walter Schloss might see both firms benefiting from the same long-term demand.
2.81%
5Y revenue/share CAGR above 1.5x ADI's 1.56%. David Dodd would look for consistent product or market expansions fueling outperformance.
14.67%
3Y revenue/share CAGR at 50-75% of ADI's 20.62%. Martin Whitman would question if the firm lags behind competitor innovations.
54.64%
10Y OCF/share CAGR 1.25-1.5x ADI's 47.51%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
22.90%
Positive OCF/share growth while ADI is negative. John Neff might see a comparative advantage in operational cash viability.
67.10%
3Y OCF/share CAGR above 1.5x ADI's 35.65%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
91.38%
Net income/share CAGR above 1.5x ADI's 60.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
23.77%
Positive 5Y CAGR while ADI is negative. John Neff might view this as a strong mid-term relative advantage.
116.01%
3Y net income/share CAGR above 1.5x ADI's 22.27%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
37.06%
10Y equity/share CAGR at 50-75% of ADI's 58.43%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
7.25%
Below 50% of ADI's 42.76%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-1.77%
Negative 3Y equity/share growth while ADI is at 12.67%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
1156.44%
10Y dividend/share CAGR above 1.5x ADI's 232.65%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
190.22%
5Y dividend/share CAGR above 1.5x ADI's 82.15%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
81.56%
3Y dividend/share CAGR above 1.5x ADI's 34.08%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
8.93%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
6.74%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-3.35%
Negative asset growth while ADI invests at 7.59%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.05%
We’re deleveraging while ADI stands at 98.20%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
5.23%
We increase R&D while ADI cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
8.89%
We expand SG&A while ADI cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.